Cutaneous T Cell Lymphoma: Update of Treatment
The state-of-the art therapy of cutaneous T cell lymphoma (CTCL) is reviewed. Commonly used treatments for early-stage (patch/plaque) mycosis fungoides (MF) include topical corticosteroids, mechlorethamine, carmustine, ultraviolet light B and PUVA. Total skin electron beam (TSEB) therapy is indicate...
Gespeichert in:
| Veröffentlicht in: | Dermatology (Basel) 1999-01, Vol.199 (2), p.102-105 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 105 |
|---|---|
| container_issue | 2 |
| container_start_page | 102 |
| container_title | Dermatology (Basel) |
| container_volume | 199 |
| creator | Zackheim, H.S. |
| description | The state-of-the art therapy of cutaneous T cell lymphoma (CTCL) is reviewed. Commonly used treatments for early-stage (patch/plaque) mycosis fungoides (MF) include topical corticosteroids, mechlorethamine, carmustine, ultraviolet light B and PUVA. Total skin electron beam (TSEB) therapy is indicated for widespread infiltrated plaque and tumor stage disease. Low-dose methotrexate is often useful for resistant patch/plaque MF and erythrodermic CTCL. Interferon α (IFN-α) is indicated for methotrexate failures and recurrent tumors following TSEB therapy. Photopheresis may be helpful for early-stage erythrodermic CTCL but is very costly. Retinoids may be of value for early and moderately advanced CTCL particularly in combination with other agents such as IFN-α and PUVA. Systemic disease usually requires combination chemotherapy such as that used for non-Hodgkin’s lymphoma; however, responses are usually short lived. |
| doi_str_mv | 10.1159/000018214 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pasca</sourceid><recordid>TN_cdi_proquest_miscellaneous_20924772</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>734899471</sourcerecordid><originalsourceid>FETCH-LOGICAL-c415t-5184b83feead33fd018c859913149ecae326d21b8a57e8cd817433283062fe243</originalsourceid><addsrcrecordid>eNpt0M9LwzAUB_AgitPpwbMgZYjgoTM_28Sb1J8wEWQ7hyxNdLNda9Ie9t-b2eJEzCUh78N7Xx4AJwiOEWLiCoaDOEZ0BxwgilEsOMG74R1-Y54kbAAOvV8GhXkq9sEAQcYES8kBGGdto1aman00jTJTFNFkXdbvVamuo1mdq8ZElY2mzqimNKvmCOxZVXhz3N9DMLu_m2aP8eTl4Sm7mcSaItbEDHE658Qao3JCbB5yaM6EQARRYbQyBCc5RnOuWGq4zjlKKSGYE5hgazAlQ3DR9a1d9dka38hy4XWI12WVGApM0xQHOPoDl1XrViGbxClDEGMBA7rskHaV985YWbtFqdxaIig3G5Q_Gwz2rG_YzkuT_5LdygI474HyWhXWqZVe-K0TCaNw0-e0Yx_KvRm3rfdTRv9Wb1-fv4Gsc0u-AHuhiHQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>275102290</pqid></control><display><type>article</type><title>Cutaneous T Cell Lymphoma: Update of Treatment</title><source>MEDLINE</source><source>Karger Journals</source><creator>Zackheim, H.S.</creator><creatorcontrib>Zackheim, H.S.</creatorcontrib><description>The state-of-the art therapy of cutaneous T cell lymphoma (CTCL) is reviewed. Commonly used treatments for early-stage (patch/plaque) mycosis fungoides (MF) include topical corticosteroids, mechlorethamine, carmustine, ultraviolet light B and PUVA. Total skin electron beam (TSEB) therapy is indicated for widespread infiltrated plaque and tumor stage disease. Low-dose methotrexate is often useful for resistant patch/plaque MF and erythrodermic CTCL. Interferon α (IFN-α) is indicated for methotrexate failures and recurrent tumors following TSEB therapy. Photopheresis may be helpful for early-stage erythrodermic CTCL but is very costly. Retinoids may be of value for early and moderately advanced CTCL particularly in combination with other agents such as IFN-α and PUVA. Systemic disease usually requires combination chemotherapy such as that used for non-Hodgkin’s lymphoma; however, responses are usually short lived.</description><identifier>ISSN: 1018-8665</identifier><identifier>EISSN: 1421-9832</identifier><identifier>DOI: 10.1159/000018214</identifier><identifier>PMID: 10559573</identifier><language>eng</language><publisher>Basel, Switzerland: Karger</publisher><subject>Administration, Topical ; Adrenal Cortex Hormones - administration & dosage ; Adrenal Cortex Hormones - therapeutic use ; Antineoplastic Agents, Alkylating - administration & dosage ; Antineoplastic Agents, Alkylating - therapeutic use ; Beta Particles ; Biological and medical sciences ; Carmustine - administration & dosage ; Carmustine - therapeutic use ; Comments ; Dermatology ; Humans ; Interferon-alpha - therapeutic use ; Lymphoma, T-Cell, Cutaneous - drug therapy ; Lymphoma, T-Cell, Cutaneous - radiotherapy ; Mechlorethamine - administration & dosage ; Mechlorethamine - therapeutic use ; Medical sciences ; Methotrexate - therapeutic use ; PUVA Therapy ; Retinoids - therapeutic use ; Skin Neoplasms - drug therapy ; Skin Neoplasms - radiotherapy ; Treatment Outcome ; Tumors of the skin and soft tissue. Premalignant lesions ; Ultraviolet Rays</subject><ispartof>Dermatology (Basel), 1999-01, Vol.199 (2), p.102-105</ispartof><rights>1999 S. Karger AG, Basel</rights><rights>1999 INIST-CNRS</rights><rights>Copyright (c) 1999 S. Karger AG, Basel</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c415t-5184b83feead33fd018c859913149ecae326d21b8a57e8cd817433283062fe243</citedby><cites>FETCH-LOGICAL-c415t-5184b83feead33fd018c859913149ecae326d21b8a57e8cd817433283062fe243</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,2427,27915,27916</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1965404$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10559573$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zackheim, H.S.</creatorcontrib><title>Cutaneous T Cell Lymphoma: Update of Treatment</title><title>Dermatology (Basel)</title><addtitle>Dermatology</addtitle><description>The state-of-the art therapy of cutaneous T cell lymphoma (CTCL) is reviewed. Commonly used treatments for early-stage (patch/plaque) mycosis fungoides (MF) include topical corticosteroids, mechlorethamine, carmustine, ultraviolet light B and PUVA. Total skin electron beam (TSEB) therapy is indicated for widespread infiltrated plaque and tumor stage disease. Low-dose methotrexate is often useful for resistant patch/plaque MF and erythrodermic CTCL. Interferon α (IFN-α) is indicated for methotrexate failures and recurrent tumors following TSEB therapy. Photopheresis may be helpful for early-stage erythrodermic CTCL but is very costly. Retinoids may be of value for early and moderately advanced CTCL particularly in combination with other agents such as IFN-α and PUVA. Systemic disease usually requires combination chemotherapy such as that used for non-Hodgkin’s lymphoma; however, responses are usually short lived.</description><subject>Administration, Topical</subject><subject>Adrenal Cortex Hormones - administration & dosage</subject><subject>Adrenal Cortex Hormones - therapeutic use</subject><subject>Antineoplastic Agents, Alkylating - administration & dosage</subject><subject>Antineoplastic Agents, Alkylating - therapeutic use</subject><subject>Beta Particles</subject><subject>Biological and medical sciences</subject><subject>Carmustine - administration & dosage</subject><subject>Carmustine - therapeutic use</subject><subject>Comments</subject><subject>Dermatology</subject><subject>Humans</subject><subject>Interferon-alpha - therapeutic use</subject><subject>Lymphoma, T-Cell, Cutaneous - drug therapy</subject><subject>Lymphoma, T-Cell, Cutaneous - radiotherapy</subject><subject>Mechlorethamine - administration & dosage</subject><subject>Mechlorethamine - therapeutic use</subject><subject>Medical sciences</subject><subject>Methotrexate - therapeutic use</subject><subject>PUVA Therapy</subject><subject>Retinoids - therapeutic use</subject><subject>Skin Neoplasms - drug therapy</subject><subject>Skin Neoplasms - radiotherapy</subject><subject>Treatment Outcome</subject><subject>Tumors of the skin and soft tissue. Premalignant lesions</subject><subject>Ultraviolet Rays</subject><issn>1018-8665</issn><issn>1421-9832</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpt0M9LwzAUB_AgitPpwbMgZYjgoTM_28Sb1J8wEWQ7hyxNdLNda9Ie9t-b2eJEzCUh78N7Xx4AJwiOEWLiCoaDOEZ0BxwgilEsOMG74R1-Y54kbAAOvV8GhXkq9sEAQcYES8kBGGdto1aman00jTJTFNFkXdbvVamuo1mdq8ZElY2mzqimNKvmCOxZVXhz3N9DMLu_m2aP8eTl4Sm7mcSaItbEDHE658Qao3JCbB5yaM6EQARRYbQyBCc5RnOuWGq4zjlKKSGYE5hgazAlQ3DR9a1d9dka38hy4XWI12WVGApM0xQHOPoDl1XrViGbxClDEGMBA7rskHaV985YWbtFqdxaIig3G5Q_Gwz2rG_YzkuT_5LdygI474HyWhXWqZVe-K0TCaNw0-e0Yx_KvRm3rfdTRv9Wb1-fv4Gsc0u-AHuhiHQ</recordid><startdate>19990101</startdate><enddate>19990101</enddate><creator>Zackheim, H.S.</creator><general>Karger</general><general>S. Karger AG</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7U7</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>19990101</creationdate><title>Cutaneous T Cell Lymphoma: Update of Treatment</title><author>Zackheim, H.S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c415t-5184b83feead33fd018c859913149ecae326d21b8a57e8cd817433283062fe243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Administration, Topical</topic><topic>Adrenal Cortex Hormones - administration & dosage</topic><topic>Adrenal Cortex Hormones - therapeutic use</topic><topic>Antineoplastic Agents, Alkylating - administration & dosage</topic><topic>Antineoplastic Agents, Alkylating - therapeutic use</topic><topic>Beta Particles</topic><topic>Biological and medical sciences</topic><topic>Carmustine - administration & dosage</topic><topic>Carmustine - therapeutic use</topic><topic>Comments</topic><topic>Dermatology</topic><topic>Humans</topic><topic>Interferon-alpha - therapeutic use</topic><topic>Lymphoma, T-Cell, Cutaneous - drug therapy</topic><topic>Lymphoma, T-Cell, Cutaneous - radiotherapy</topic><topic>Mechlorethamine - administration & dosage</topic><topic>Mechlorethamine - therapeutic use</topic><topic>Medical sciences</topic><topic>Methotrexate - therapeutic use</topic><topic>PUVA Therapy</topic><topic>Retinoids - therapeutic use</topic><topic>Skin Neoplasms - drug therapy</topic><topic>Skin Neoplasms - radiotherapy</topic><topic>Treatment Outcome</topic><topic>Tumors of the skin and soft tissue. Premalignant lesions</topic><topic>Ultraviolet Rays</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zackheim, H.S.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Toxicology Abstracts</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Dermatology (Basel)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zackheim, H.S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cutaneous T Cell Lymphoma: Update of Treatment</atitle><jtitle>Dermatology (Basel)</jtitle><addtitle>Dermatology</addtitle><date>1999-01-01</date><risdate>1999</risdate><volume>199</volume><issue>2</issue><spage>102</spage><epage>105</epage><pages>102-105</pages><issn>1018-8665</issn><eissn>1421-9832</eissn><abstract>The state-of-the art therapy of cutaneous T cell lymphoma (CTCL) is reviewed. Commonly used treatments for early-stage (patch/plaque) mycosis fungoides (MF) include topical corticosteroids, mechlorethamine, carmustine, ultraviolet light B and PUVA. Total skin electron beam (TSEB) therapy is indicated for widespread infiltrated plaque and tumor stage disease. Low-dose methotrexate is often useful for resistant patch/plaque MF and erythrodermic CTCL. Interferon α (IFN-α) is indicated for methotrexate failures and recurrent tumors following TSEB therapy. Photopheresis may be helpful for early-stage erythrodermic CTCL but is very costly. Retinoids may be of value for early and moderately advanced CTCL particularly in combination with other agents such as IFN-α and PUVA. Systemic disease usually requires combination chemotherapy such as that used for non-Hodgkin’s lymphoma; however, responses are usually short lived.</abstract><cop>Basel, Switzerland</cop><pub>Karger</pub><pmid>10559573</pmid><doi>10.1159/000018214</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1018-8665 |
| ispartof | Dermatology (Basel), 1999-01, Vol.199 (2), p.102-105 |
| issn | 1018-8665 1421-9832 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_20924772 |
| source | MEDLINE; Karger Journals |
| subjects | Administration, Topical Adrenal Cortex Hormones - administration & dosage Adrenal Cortex Hormones - therapeutic use Antineoplastic Agents, Alkylating - administration & dosage Antineoplastic Agents, Alkylating - therapeutic use Beta Particles Biological and medical sciences Carmustine - administration & dosage Carmustine - therapeutic use Comments Dermatology Humans Interferon-alpha - therapeutic use Lymphoma, T-Cell, Cutaneous - drug therapy Lymphoma, T-Cell, Cutaneous - radiotherapy Mechlorethamine - administration & dosage Mechlorethamine - therapeutic use Medical sciences Methotrexate - therapeutic use PUVA Therapy Retinoids - therapeutic use Skin Neoplasms - drug therapy Skin Neoplasms - radiotherapy Treatment Outcome Tumors of the skin and soft tissue. Premalignant lesions Ultraviolet Rays |
| title | Cutaneous T Cell Lymphoma: Update of Treatment |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T01%3A45%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cutaneous%20T%20Cell%20Lymphoma:%20Update%20of%20Treatment&rft.jtitle=Dermatology%20(Basel)&rft.au=Zackheim,%20H.S.&rft.date=1999-01-01&rft.volume=199&rft.issue=2&rft.spage=102&rft.epage=105&rft.pages=102-105&rft.issn=1018-8665&rft.eissn=1421-9832&rft_id=info:doi/10.1159/000018214&rft_dat=%3Cproquest_pasca%3E734899471%3C/proquest_pasca%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=275102290&rft_id=info:pmid/10559573&rfr_iscdi=true |